使用生理学基础的药物动力学建模,根据第一阶段临床数据,对吸入伊特拉科纳的药物相互作用潜力的评估
Mackenzie Bergagnini-Kolev1, Katie Kane2, Ian E Templeton1
1Simcyp Ltd (Division of Certara), Seattle, Washington, USA.
吸入伊特拉科纳 (PUR1900) 显示药物相互作用风险最小. 基于生理学的药物动力学建模证实了低系统性暴露,减少了对细胞染色体P450 3A4抑制的担忧.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药理动力学 药理动力学
- 药物开发 药物开发
背景情况:
- 伊特拉科纳是一种细胞染色体P450 3A4 (CYP3A4) 抑制剂,导致显著的药物相互作用 (DDI).
- PUR1900是一种吸入式的伊特拉科纳制剂,专为高肺部和低全身暴露而设计.
- 评估吸入药物的DDI潜力对于患者安全至关重要.
研究的目的:
- 通过使用生理学基础的药理动力学 (PBPK) 建模,评估吸入性伊特拉科纳 (PUR1900) 的药物相互作用 (DDI) 潜力.
- 为了确定 PUR1900 抑制 CYP3A4 的风险,当 PUR1900 与探针基质米达佐拉姆 (Midazolam) 联合使用时.
- 评估PUR1900在服用相互作用药物的患者中的安全性.
主要方法:
- 使用生理学基础的药理动力学 (PBPK) 建模,优化了现有的伊特拉可纳模型与第一阶段临床试验数据.
- 静态模型和PBPK模拟用于预测Midazolam作为受害者药物的DDI潜力.
- 在一个虚拟健康的人群中,以PUR1900的治疗剂量 (高达40毫克/天) 进行模拟.
主要成果:
- 最初的静态模型表明DDI的可能性很高.
- 用临床数据验证的PBPK建模表明了最小的DDI潜力.
- 在最高PUR1900剂量时,米达佐拉姆Cmax和AUC的几何平均比分分别为1.14和1.26,这意味着相互作用最小.
结论:
- 低系统暴露的吸入性伊特拉科纳 (PUR1900) 导致微不足道的CYP3A4抑制.
- 预计PUR1900的显著DDI风险大大低于口服伊特拉科纳.
- PUR1900可能为在服用相互作用药物的患者治疗肺部真菌感染提供更安全的替代方案.
更多相关视频
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
06:09Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Inhaled Medications
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
